Ending Cervical Cancer
Hope is on the horizon. Thanks to cutting-edge research and science, much of which has been led by researchers at BC Women’s Hospital + Health Centre, in collaboration with other experts and agencies in the field, we now have the answers to end cervical cancer at home and abroad.
- "Cervical cancer is one of the gravest threats to women’s lives… most of these women have not been diagnosed, nor do they have access to treatment that could cure them or prolong their lives." World Health Organization
Every year, 270,000 women worldwide and between 400-600 women in Canada die from cervical cancer. It is one of the world’s deadliest but most easily preventable forms of cancer. Projections estimate that by 2030, almost half a million women will die annually of cervical cancer.
- Cervical cancer has been definitively linked to the Human Papilloma Virus (HPV) and impacts women in the prime of their life. HPV is the most common sexually transmitted infection. Cervical cancer kills women, leaves children motherless, devastates families and cripples communities.Cervical cancer impacts women in the prime of their life, typically between the ages of 30-50 years. It is a disease that preys on women with the least resources, those who are marginalized, immigrant, Aboriginal, women of colour or low-income, whether they live here in Canada or in developing nations.
- Armed with a vaccine that prevents infection, BC Women’s research team is taking the lead on innovating screening tests for early detection, protocols for inoculation and model treatments for cervical cancer. Like the eradication of polio, we have the tools and knowledge to eliminate this deadly cancer.
We have the ability to eliminate the HPV virus from the general population, saving many more women’s lives and reduce the drain on precious health resources.
Women and girls in Canada and in developing nations continue to die needlessly from a cancer that is completely preventable. We have the answers – it’s time to put an end to cervical cancer.
- The World Health Organization is poised to act on the guidance of experts. BC Women’s Hospital is leading the challenge to develop a roadmap that ensures women and girls worldwide have equitable access to prevention and treatment.
BC Women’s research team, led by world renowned scientists Dr. Gina Ogilvie (pictured left) and Dr. Deborah Money, continues to break new ground and lead transformational new knowledge and practices.
BC Women’s is home to the world’s leading experts in HPV, writing the national and informing international guidelines on the HPV vaccine and screening. The team has influenced global policy on cervical cancer prevention through the 2 dose vaccine, and helped to create innovative methods for cost-effective screening that is saving women’s lives in developing countries.
This outstanding team has the capacity to provide the WHO with the tools and methods it needs to eradicate cervical cancer.
BC Women’s with its PHSA partners comprise a unique team of multidisciplinary researchers and is one of the only areas of cancer where scientists from the fields of infectious diseases, obstetrics, oncology, virology, and vaccinology are working together to create and share new knowledge to put an end to this deadly disease.
With expertise across the entire spectrum of cervical cancer issues, from primary prevention to surgical intervention, BC Women’s has the proven track record, funding of more than $35 million from research institutes, and the ability to deliver tangible results. We can be a catalyst for global change.
- Together we can find the right combination of effective and affordable tools to prevent and treat cervical cancer at home and abroad. Supporting the experts’ ability to finish charting this journey will mean the difference between life and death for millions of women and girls.
Ending cervical cancer is akin to the eradication of polio. Once a disease feared worldwide that paralyzed people for life, the invention of the polio vaccine and roll-out of global vaccination programs has reduced polio among the world’s population by 99%. Today it survives only in the most marginalized and poorest communities. BC Women’s is poised to do for cervical cancer what the polio vaccination has done to polio.
The Global Eradication of Cervical Cancer can be accomplished. We have the plan.
All we need is you.
The tools are before us to turn cervical cancer into a distant memory. This deadly cancer can become the next global disease eradication success. It is a lofty goal, but one that is completely accomplishable within our lifetime.
Finding the right combination of effective and affordable tools to prevent and treat cervical cancer at home and abroad will mean the difference between life and death for millions of women and girls.
The answer is within our reach - please make a donation to help realize the end of cervical cancer.
- BC Women’s has a proven track record. Cervical cancer can be eliminated while also learning more about dealing with other viral‑based cancers. By donating to BC Women’s, your investment delivers tangible results and will be a catalyst for worldwide change.
BC Women’s Hospital Foundation is raising funds to support the life-saving, multi-disciplinary research being led by BC Women’s and its collaborating scientific partners that will end this disease for all women, nationally and internationally.
Funds will advance research into prevention, intervention, treatment and ultimately, the eradication of cervical cancer.
It’s about propelling Canada’s leadership in medical advancement, enhancing resources, benefitting economies, keeping families together and most importantly, saving women’s lives.
Help lead the global effort to eradicate cervical cancer by making a donation.
- Leading research positions, training and service in women’s reproductive and maternal health, BC Women’s as an international leader in creating new knowledge and advancement in practice-changing projects, putting an end cervical cancer.
Dr. Gina Ogilvie, Canada Research Chair, Global Control of HPV-related Diseases and Women’s Cancers; Assistant Director, Women's Health Research Institute, BC Women's Hospital + Health Centre, Professor, Faculty of Medicine, UBC and a physician at BC Women’s. Dr. Ogilvie is leading a $6 million clinical trial – The HPV Focal Study - comparing HPV testing to pap screening, the only one of its kind in North America with results that will inform international health policy guidelines. Dr. Ogilvie is also the global lead for ASPIRE (Advances in Screening and Prevention in Reproductive Cancers), an international partnership examining innovative methods to prevent cancers for women in low and middle income setting. Her work is supported by global partners, and is highly influential in establishing policies to bridge the cancer divide for women. She has over 80 peer reviewed publications and stewards over $25 million dollars in research grants in the field of women’s health.
Dr. Deborah Money, Executive Vice Dean, Faculty of Medicine, UBC, and former VP Research at BC Women's hospital, is one of only 5 clinical researchers in Canada with specialized training in Reproductive Infectious Disease. Dr. Money is internationally recognized for her ground-breaking work including the prevention of mother-to-child HIV transmission, infectious diseases in pregnancy, and HPV (human papillomavirus) and cervical cancer. She currently leads CIHR funded studies on the impact of the HPV vaccine on HIV+ girls. Dr. Money is a global leader in research on the prevention of preterm birth through the understanding of the vaginal microbiome; and the use of genomic technology to generate simple diagnostic and personalized therapy for women at risk. She is Past President of the International Infectious Diseases Society of Obstetrics and Gynaecology and a leading creator of provincial and national guidelines for the treatment of HIV in pregnancy. Dr. Money has published over 130 peer reviewed journals and currently stewards over $10 million in research grants.